Liposomal Formulations pharmacokinetics and Tissue Distribution
Distribution of chemotherapeutic agents such as Doxorubicin and Paclitaxel into untargeted organs causes toxicity. Non liposomal Doxorubicin formulation causes myocardium damage that is cumulative and irreversible. In clinical practice, the cumulative dose of Doxorubicin must be limited to reduce cardiotoxicity. The development of chemotherapeutic agents to effectively treat solid tumors depends on the ability of these agents to achieve cytotoxic drug exposure within the tumor(s). Encapsulating common anticancer agents into nanoparticle delivery systems, particularly liposomes, provides a promising approach to enhance delivery at target site. Liposomes are phospholipid bilayer vesicles, which can be used as delivery vehicles for chemotherapeutics. Liposomal Doxorubicin formulations have shown significant therapeutic advantages of lower toxicity and equivalent or higher anti-tumor effects compared to free Doxorubicin formulations. Because only free Doxorubicin has toxicological and ph...